Small molecule and peptide CXCR4 antagonists. A patent review from 2019 to 2024 [0.03%]
CXCR4小分子和肽类拮抗剂的专利回顾（2019-2024）
Zafer Sahin,Yesim A Tahirovic,Jiafeng Geng et al.
Zafer Sahin et al.
Introduction: The chemokine receptor CXCR4 has been under intense study due to the central role it plays in immune system regulation and the pathology of human disease. Although the first CXCR4 drug plerixafor emerged ove...
Yanfang Chen,Huanmin Zhou,Jiamin Yu et al.
Yanfang Chen et al.
Introduction: Bromodomain-containing protein 4 (BRD4) stands as a pivotal member within the Bromodomain and Extra-Terminal Domain (BET) family, contributing significantly to epigenetic control and gene expression. Given i...
Small molecules targeting immune checkpoint proteins for cancer immunotherapy: a patent and literature review (2020-2024) [0.03%]
靶向免疫检查点蛋白的小分子化合物在癌症免疫治疗中的应用：专利与文献分析（2020-2024）
Qiaohong Geng,Juanjuan Xu,Chunsheng Du et al.
Qiaohong Geng et al.
Introduction: Targeting immune checkpoint proteins (ICPs) via small molecules open a new window for cancer immunotherapy. Herein, we summarize recent advances of small molecules with novel chemical structures targeting IC...
A patent review of von Hippel-Lindau (vhl)-recruiting chemical matter: E3 ligase ligands for PROTACs and targeted protein degradation (2019-present) [0.03%]
2019年至今的HIFPRO招募化合物专利回顾：E3连接酶配体在PROTAC和靶向蛋白降解中的应用
Aina Urbina,Alex J Hallatt,Jack Robertson et al.
Aina Urbina et al.
Introduction: The von Hippel-Lindau (VHL) E3 ubiquitin ligase has seen extensive research due to its involvement in the ubiquitin proteasome system and role as a tumor suppressor within the hypoxia signaling pathway. VHL ...
Patent review of novel compounds targeting opioid use disorder (2018-2024) [0.03%]
2018至2024年阿片类药物使用障碍领域新型化合物的专利评审综述
Samuel Obeng,Lance R McMahon,Edward Ofori
Samuel Obeng
Introduction: Opioids have served as a cornerstone in pain management for decades. However, the emergence of increasingly potent synthetic analogs brings forth a range of side effects, including respiratory depression, to...
Daniel H O Donovan,Weiping Wang,Jim Sheppeck et al.
Daniel H O Donovan et al.
Histamine H3 receptor antagonists/inverse agonists: a patent review (October 2017 - December 2023) documenting progress [0.03%]
组胺H3受体拮抗剂/部分激动剂(2017年10月-2023年12月):专利文献述评及研发进展文档化
Dorota Łażewska,Katarzyna Kieć-Kononowicz
Dorota Łażewska
Introduction: Histamine H3 receptor antagonists/inverse agonists, since the discovery of histamine H3 receptor (H3R), are important ligands in the search for new potential drugs. The most interesting are CNS diseases as t...
Chang Liu,Qing Mao,Bing Zhang et al.
Chang Liu et al.
Introduction: Xanthine oxidase (XO) catalyzes the oxidation of both hypoxanthine and xanthine in the last two steps of the purine metabolic pathway, serving as a rate-limiting enzyme for uric acid production as well as a ...
Small molecule ATM inhibitors as potential cancer therapy: a patent review (2003-present) [0.03%]
小分子ATM抑制剂作为癌症治疗的潜在药物：2003年至今专利回顾
Yan A Ivanenkov,Alexander S Malyshev,Alexander S Malyshev et al.
Yan A Ivanenkov et al.
Introduction: The ataxia telangiectasia mutated kinase (ATM) is key in coordinating the DDR signaling network essential for responding to double-strand breaks (DSBs). Several ATM inhibitors are being investigated for pote...
Patent landscape of small molecule inhibitors of METTL3 (2020-present) [0.03%]
2020年以来METTL3小分子抑制剂专利布局分析
Zhixing Wu,Alexis R Smith,Zhijian Qian et al.
Zhixing Wu et al.
Introduction: Methyltransferase-like protein 3 (METTL3), in complex with METTL14, is the key 'writer' protein for RNA m6A methylation, accounting for almost all mRNA m6A modifications. Recent studies reveal that METTL3 is...